Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Myriad Genetics, Inc. announces participation in upcoming healthcare conferences and fourth quarter earnings conference call. Management will provide financial overview, business update, and guidance for 2024. Live webcast available for investors.
02/21/2024 - 04:05 PM
Management will also participate in two upcoming healthcare conferences
SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes.
During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2023. Revenue and earnings guidance for 2024 will also be shared.
A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com . To participate in the live conference call via telephone, please register here . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. Following the conference call, an archived webcast of the call will be available at investor.myriad.com .
March Investor Conferences Management will also be participating in the following investor conferences:
The 45th Annual Raymond James & Associates Institutional Investors Conference with a presentation from Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, on March 4, 2024, at 4:35pm EST. The 44th Annual Cowen Health Care Conference with a fireside chat featuring Sam Raha, chief operating officer, and Ben Wheeler, chief financial officer – operations, on March 5, 2024, at 12:50pm EST. A live and archived webcast of both presentations can be viewed in the investor relations section of Myriad’s website at investor.myriad.com .
About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com .
Investor Contact Matt Scalo (801) 584-3532IR@myriad.com
Media Contact Glenn Farrell (385) 318-3718PR@myriad.com
When is Myriad Genetics, Inc. holding its fourth quarter earnings conference call?
Myriad Genetics, Inc. will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST.
Where can investors access the live webcast of the earnings conference call?
Investors can access the live webcast of the earnings conference call on Myriad's Investor Relations website at investor.myriad.com.
Which two healthcare conferences will Myriad Genetics, Inc. participate in?
Myriad Genetics, Inc. will participate in the 45th Annual Raymond James & Associates Institutional Investors Conference on March 4, 2024, and the 44th Annual Cowen Health Care Conference on March 5, 2024.
Who will be presenting at the Raymond James & Associates Institutional Investors Conference?
Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, will be presenting at the 45th Annual Raymond James & Associates Institutional Investors Conference.
What will be discussed at the healthcare conferences?
The conferences will feature presentations and fireside chats providing insights into the company's operations and financial performance.
Where can investors view the live and archived webcasts of the conference presentations?
Investors can view the live and archived webcasts of the conference presentations in the investor relations section of Myriad's website at investor.myriad.com.
MYGN Rankings
#4003 Ranked by Stock Gains
MYGN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Salt Lake City
About MYGN
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.